Ascentage Pharma Group International

OTCPK:ASPH.F Stock Report

Market Cap: US$1.6b

Ascentage Pharma Group International Management

Management criteria checks 3/4

Ascentage Pharma Group International's CEO is Dajun Yang, appointed in Jan 2009, has a tenure of 17.42 years. total yearly compensation is CN¥41.77M, comprised of 98% salary and 2% bonuses, including company stock and options. directly owns 6.32% of the company’s shares, worth $103.55M. The average tenure of the management team and the board of directors is 4.3 years and 6.1 years respectively.

Key information

Dajun Yang

Chief executive officer

CN¥41.8m

Total compensation

CEO salary percentage98.00%
CEO tenure17.4yrs
CEO ownership6.3%
Management average tenure4.3yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dajun Yang's remuneration changed compared to Ascentage Pharma Group International's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025CN¥42mCN¥41m

-CN¥1b

Sep 30 2025n/an/a

-CN¥1b

Jun 30 2025n/an/a

-CN¥1b

Mar 31 2025n/an/a

-CN¥782m

Dec 31 2024CN¥4mCN¥4m

-CN¥405m

Sep 30 2024n/an/a

-CN¥383m

Jun 30 2024n/an/a

-CN¥360m

Mar 31 2024n/an/a

-CN¥643m

Dec 31 2023CN¥5mCN¥5m

-CN¥926m

Sep 30 2023n/an/a

-CN¥902m

Jun 30 2023n/an/a

-CN¥879m

Mar 31 2023n/an/a

-CN¥881m

Dec 31 2022CN¥4mCN¥4m

-CN¥883m

Sep 30 2022n/an/a

-CN¥848m

Jun 30 2022n/an/a

-CN¥812m

Mar 31 2022n/an/a

-CN¥797m

Dec 31 2021CN¥5mCN¥5m

-CN¥782m

Sep 30 2021n/an/a

-CN¥759m

Jun 30 2021n/an/a

-CN¥735m

Mar 31 2021n/an/a

-CN¥706m

Dec 31 2020CN¥4mCN¥4m

-CN¥678m

Sep 30 2020n/an/a

-CN¥922m

Jun 30 2020n/an/a

-CN¥1b

Mar 31 2020n/an/a

-CN¥1b

Dec 31 2019CN¥4mCN¥3m

-CN¥1b

Compensation vs Market: Dajun's total compensation ($USD6.18M) is about average for companies of similar size in the US market ($USD5.29M).

Compensation vs Earnings: Dajun's compensation has increased whilst the company is unprofitable.

CEO

Dajun Yang (63 yo)

17.4yrs
Tenure
CN¥41,774,000
Compensation

Dr. Dajun Yang, M.D., Ph D, co-founded Ascentage Pharma Group International in 2009 and serves as its Chairman from 2017 and has been its Director since November 17, 2017 and serves as its CEO since 2009....

Leadership Team

NamePositionTenureCompensationOwnership
Dajun Yang
Co-Founder17.4yrsCN¥41.77m6.32%
$ 103.5m
Shaomeng Wang
Co-Founderno dataCN¥1.91m2.73%
$ 44.8m
Ming Guo
Co-Founder17.1yrsno data3.6%
$ 58.9m
Veet Misra
Chief Financial Officerless than a yearno datano data
Yuly Chen
Senior Director of Investor Relationsno datano datano data
Thomas Knapp
Senior VP & General Counsel7.3yrsno data0.098%
$ 1.6m
Yifan Zhai
Chief Medical Officer12.9yrsno data0.11%
$ 1.8m
Chongdong Fu
Senior VP & Head of CMCno datano datano data
Jin Cao
Head of Financeno datano data0.0015%
$ 24.1k
Zhichao Si
Head of Commercial1.4yrsno datano data
Manish Tandon
SVP of Business Developmentless than a yearno datano data
Hoi Yan Leung
Company Secretaryless than a yearno datano data
4.3yrs
Average Tenure
63yo
Average Age

Experienced Management: ASPH.F's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dajun Yang
Co-Founder8.6yrsCN¥41.77m6.32%
$ 103.5m
Shaomeng Wang
Co-Founder8.6yrsCN¥1.91m2.73%
$ 44.8m
Allen S. Lichter
Chairman of the Clinical Advisory Board3.4yrsno datano data
Marina S. Bozilenko
Independent Non-Executive Director1.6yrsCN¥724.00kno data
Paul A. Bunn
Member of Clinical Advisory Boardno datano datano data
David Sidransky
Lead Independent Non-Executive Director5.3yrsCN¥737.00k0.0029%
$ 47.4k
Jedd D. Wolchok
Member of Clinical Advisory Board5.2yrsno datano data
Arul M. Chinnaiyan
Member of Clinical Advisory Boardno datano datano data
Changqing Ye
Independent Non-Executive Director7yrsCN¥737.00k0.0024%
$ 40.0k
Dazhong Lu
Independent Non-Executive Director7.9yrsCN¥295.00k0.011%
$ 184.6k
Wei Ren
Independent Non-Executive Director7yrsCN¥737.00k0.0024%
$ 40.0k
Asher A. Chanan-Khan
Member of Clinical Advisory Board3.4yrsno datano data
6.1yrs
Average Tenure
61yo
Average Age

Experienced Board: ASPH.F's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/15 12:50
End of Day Share Price 2026/06/05 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ascentage Pharma Group International is covered by 24 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yang HuangBofA Global Research
Mayank MamtaniB. Riley Securities, Inc.
Suranjit MukherjeeBTIG